University of Colorado Health Sciences Center
Welcome,         Profile    Billing    Logout  
 20 Trials 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bull, Sheana
NCT03973931: Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

Active, not recruiting
N/A
9501
US
Nudge
University of Colorado, Denver, National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Adherence, Medication, Medication Adherence, Diabetes Mellitus, Hypertension, Hyperlipidemias, Coronary Artery Disease, Atrial Fibrillation
01/24
06/24
Nick, Jerry A
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
IMPACT, NCT04735952: Improving P. Aeruginosa Detection With Breath-based Diagnostics (-Breath)

Recruiting
N/A
300
Canada, US
University of British Columbia, Arizona State University, Children's Hospital Colorado, National Heart, Lung, and Blood Institute (NHLBI), Cystic Fibrosis Foundation
Cystic Fibrosis
11/24
12/24
STEADY, NCT05822102: Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY

Enrolling by invitation
N/A
100
US
National Jewish Health
Cystic Fibrosis
09/23
09/23
POSTSTAMP, NCT06262282: Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

Enrolling by invitation
N/A
10
US
mycobacteriophage
National Jewish Health, Cystic Fibrosis Foundation
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
12/26
12/28
PAINLESS, NCT04579211: Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening

Enrolling by invitation
N/A
220
US
urine lipoarabinomannan (LAM)
Jerry A. Nick, M.D.
Cystic Fibrosis
10/25
10/25
PREDICT, NCT02073409: Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

Enrolling by invitation
N/A
200
US
National Jewish Health, Cystic Fibrosis Foundation, Children's Hospital Colorado
Cystic Fibrosis
03/25
03/25
PATIENCE, NCT02419989: Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis

Enrolling by invitation
N/A
70
US
National Jewish Health, Cystic Fibrosis Foundation, Children's Hospital Colorado
Cystic Fibrosis
03/25
03/25
Leehey, Maureen
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Badesch, David B
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Terminated
3
10
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension
04/23
04/23
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
NCT05798923: A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

Recruiting
2
15
US
LAM-001
OrphAI Therapeutics
Pulmonary Hypertension
12/24
12/25
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Bull, Todd M
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Recruiting
2
20
US
Adempas, Riociguat
University of Colorado, Denver, Bayer
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
12/24
12/24
CHORUS, NCT06259292: Comprehensive HHT Outcomes Registry of the United States

Recruiting
N/A
10000
US
Cure HHT, Augusta University, The Cleveland Clinic, Mayo Clinic, Massachusetts General Hospital, Columbia University, Oregon Health and Science University, University of California, Los Angeles, University of California, San Francisco, University of Colorado, Denver, University of North Carolina, Chapel Hill, University of Pennsylvania, University of Texas, University of Utah, Washington University School of Medicine, Yale University, Health Resources and Services Administration (HRSA), Children's Hospital of Philadelphia
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
11/33
11/33
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Camidge, Ross D
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT05845671: Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Recruiting
1/2
12
US
Amivantamab 1050mg, JNJ-61186372, Amivantamab 1400mg, Amivantamab (to be determined)
University of Colorado, Denver, Janssen Research & Development, LLC
Lung Cancer, Non Small Cell Lung Cancer
01/27
01/28
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT04227028: Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Active, not recruiting
1
5
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113
City of Hope Medical Center, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
06/25
Leong, Stephen
NCT03891784: Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Active, not recruiting
2
20
US
Abemaciclib, Verzenio, 1231929-97-7, 2-Pyrimidinamine
University of Washington, Eli Lilly and Company
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Neoplasm, Midgut Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Refractory Digestive System Neuroendocrine Neoplasm
09/25
09/26
Moulden, Kelly
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
Nguyen, Ana
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
Schenk, Erin
HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting
1/2
232
US
MK-6070, HPN328, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
02/26
02/26
NCT05845671: Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Recruiting
1/2
12
US
Amivantamab 1050mg, JNJ-61186372, Amivantamab 1400mg, Amivantamab (to be determined)
University of Colorado, Denver, Janssen Research & Development, LLC
Lung Cancer, Non Small Cell Lung Cancer
01/27
01/28
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
12/24
12/24
ZWI-ZW171-10, NCT06523803: A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

Recruiting
1
160
Europe, US
ZW171
Zymeworks BC Inc.
Mesothelin-expressing Advanced Cancers
11/27
12/27
NCT01580982: Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Recruiting
N/A
175
US
University of Colorado, Denver
Lung Neoplasms
01/26
01/27
NCT03042221: Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Recruiting
N/A
100
US
University of Colorado, Denver
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
11/26
09/27
Mehner, Lauren C
ROP3, NCT04634604: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Terminated
3
16
Canada, US
Bevacizumab, Avastin, Laser
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
08/23
08/23

Download Options